FILE:CELG/CELG-8K-20100106160545.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
o
o
o
 
 
 
ITEM 8.01 OTHER EVENTS
On January 6, 2010, Celgene Corporation announced that its Chairman and Chief Executive Officer Sol J. Barer, Ph.D., will provide an overview of the company at the 28 Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010 at 11:00 a.m. EST.
th
Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1  Press Release dated January 6, 2010
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CELGENE CORPORATION

Exhibit 99.1
today announced its presentation at the 28 Annual JPMorgan Healthcare Conference on Monday, January 11, 2010 at 8:00 AM PST (11:00 AM EST) will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company.
SUMMIT, NJ  (January 6, 2010)  Celgene Corporation (NASDAQ: CELG)
th
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.


